Ascentage Pharma presented results from five preclinical studies at AACR 2025, showcasing innovative drug candidates targeting hematological malignancies and solid tumors.
A comprehensive pipeline analysis reveals over 25 pharmaceutical companies actively developing approximately 30 drug candidates for nasopharyngeal cancer, signaling significant industry investment in this therapeutic area.
Olverembatinib demonstrates promising efficacy and safety as a second-line treatment for chronic phase chronic myeloid leukemia (CP-CML) patients without the T315I mutation.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.